NLRP3 inflammasome blockade by treatment of mice with the inhibitor MCC950 suppressed lymphoma growth and ameliorated antitumor immunity by downregulating PD-L1 in the tumor microenvironment (TME) and decreasing the proportion of programmed cell death protein 1 (PD-1)/T-cell immunoglobulin and mucin-domain containing three (TIM-3)-expressing T-cells, MDSCs, tumor-associated macrophages (TAMs), and regulatory T-cells [86]. Here, NLRP3 is linked to lymphoma.